证券代码：603811 证券简称：诚意药业 公告编号：2023-024 浙江诚意药业股份有限公司 关于2023年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江诚意药业股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日上午 09:00-10:00 在上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 通过网络文字互动方式召开 2023 年半年度业绩说明会。现将有关事项公告如下： 一、业绩说明会召开情况 2023 年 8 月 17 日，公司在上海证券交易所网站（www.sse.com.cn）及指定信 息媒体披露了《浙江诚意药业股份有限公司关于召开 2023 年半年度业绩说明会的 公告》（公告编号：2023-019）。 2023 年 8 月 25 日上午 09:00-10:00，公司总经理赵春建先生、副总经理任秉 钧先生、副总经理厉市生先生、董事会秘书柯泽慧女士、财务总监吕孙战先生、独 立董事陈志刚先生出席了本次业绩说明会。与投资者进行互 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥320.86 million, a slight increase of 0.85% compared to ¥318.16 million in the same period last year[20]. - Net profit attributable to shareholders of the listed company reached approximately ¥90.60 million, representing a significant increase of 39.48% from ¥64.96 million in the previous year[20]. - The net cash flow from operating activities increased by 50.63% to approximately ¥107.39 million, up from ¥71.29 million in the same period last year[20]. - Basic earnings per share rose to ¥0.28, a 40% increase compared to ¥0.20 in the same period last year[21]. - The weighted average return on net assets increased to 8.06%, up by 1.62 percentage points from 6.44% in the previous year[21]. - The total assets of the company at the end of the reporting period were approximately ¥1.79 billion, an increase of 4.19% from ¥1.72 billion at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 2.95% to approximately ¥1.12 billion, compared to ¥1.09 billion at the end of the previous year[20]. - The increase in net profit was primarily due to a significant rise in investment income and a reduction in losses from the subsidiary Jiangsu Chengyi[22]. Market Position and Product Development - The company secured over 41% market share for its main product, Glucosamine Hydrochloride Capsules, in nine provinces[28]. - Four new health food products were launched, with plans for multi-channel promotion to drive sales growth[29]. - The company is actively participating in national pharmaceutical bidding, with significant success in securing contracts[28]. - The company has ten new products under research, including L-Carnitine Injection and Voriconazole API, which have been successfully accepted for filing[29]. - The company plans to enhance its product line through ongoing research and potential acquisitions in the oncology and liver protection sectors[30]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million allocated for potential deals[75]. Operational Efficiency and Management - The company plans to continue focusing on investment opportunities and improving operational efficiency to sustain growth in the future[22]. - The company has implemented comprehensive risk management strategies to ensure sustainable sales growth[28]. - The company’s marketing center in Shanghai aims to build a robust global sales network by recruiting top marketing talent[28]. - Ongoing research and development efforts have led to the introduction of two new technologies that are anticipated to enhance operational efficiency by 10%[76]. - The company is focusing on enhancing its technological capabilities to improve operational efficiency and product offerings[138]. Environmental Compliance and Sustainability - The company maintained compliance with environmental regulations, with no pollution incidents reported during the reporting period[51]. - The company has implemented a combination of clean production and end-of-pipe treatment to enhance environmental protection efforts[56]. - The company has taken measures to reduce carbon emissions, including solar rooftop photovoltaic power generation and smart energy digital management[70]. - The company has established an emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[67]. Shareholder and Capital Management - The company did not propose any profit distribution or capital reserve transfer plans for the half-year period[48]. - The company has a commitment to stabilize its stock price for three years following its IPO, with conditions based on stock performance over 20 consecutive trading days[83]. - If the stock price falls below the latest audited net asset value per share, the company and its major shareholders will initiate measures to stabilize the stock price[83]. - The company plans to repurchase shares to stabilize the stock price, subject to legal and regulatory compliance[84]. - Shareholders must approve any share repurchase decision with at least two-thirds of the voting rights at the meeting[84]. Financial Health and Investments - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2023, representing a 20% year-over-year growth[75]. - The total assets of the company at the end of the reporting period are 1,087,885,213.00, showing a growth from 986,308,389.00 in the previous year[142]. - The company has allocated 90,599,041.00 for capital reserves, which is a strategic move to strengthen its financial position[139]. - The overall equity of the company increased to 994,681,383 RMB, reflecting strong financial health and investor confidence[153]. Governance and Compliance - The company has established a structured governance framework, including a board of directors and various specialized committees[161]. - The financial statements comply with the disclosure requirements set forth by the China Securities Regulatory Commission[164]. - The company adheres to the Chinese Accounting Standards, ensuring that the financial statements accurately reflect its financial position and operating results[167].

证券代码：603811 证券简称：诚意药业 公告编号：2023-019 浙江诚意药业股份有限公司 关于召开2023年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 会议召开时间：2023 年 08 月 25 日(星期五)上午 09:00-10:00 ● 会议召开网址：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） ● 会议召开方式：上证路演中心网络文字互动方式 ● 投资者可于 2023 年 08 月 18 日(星期五)至 08 月 24 日(星期四)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）将于 2023 年 08 月 24 日发布 公司 2023 年半年度报告，为便于广大投资者更全面深 ...

证券代码：603811 证券简称：诚意药业 公告编号：2023-013 浙江诚意药业股份有限公司 关于参加沪市主板生物医药行业上市公司 2022 年年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 05 月 05 日(星期五) 至 05 月 11 日(星期四)16:00 前登 录上证路演中心网站首页，点击"提问预征集"栏目或通过公司邮箱 office@chengyipharma.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 浙江诚意药业股份有限公司（以下简称"公司"）已于 2023 年 04 月 26 日发 布 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度的经营 成果、财务状况，同时更加充分地向投资者展示生物医药行业发展情况，公司计 划于 2023 年 05 月 12 日 上午 10:00-11:00 参加沪市主板医药行业上市公司 2022 年年报集体业绩说明会，就投资者关心的问题进行交流。 一、 说明 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥147,830,388.05, representing a decrease of 7.40% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥39,749,555.71, an increase of 37.44% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥38,805,216.40, up by 25.50% compared to the previous year[6]. - The net profit for Q1 2023 was CNY 39,622,334.78, representing a 37% increase compared to CNY 28,958,813.98 in Q1 2022[21]. - Operating profit for Q1 2023 reached CNY 41,796,167.73, up 24% from CNY 33,595,681.95 in the same period last year[21]. - The company reported a total comprehensive income of CNY 39,623,926.08 for Q1 2023, compared to CNY 28,943,664.77 in Q1 2022, indicating a 37% growth[22]. Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.17, representing a growth of 41.67%[6]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.17, up from CNY 0.12 in Q1 2022[22]. Cash Flow and Liquidity - The net cash flow from operating activities was ¥47,267,096.86, reflecting a 39.42% increase year-on-year[6]. - Cash flow from operating activities showed a net increase of CNY 47,267,096.86, compared to CNY 33,901,895.37 in the previous year, marking a 39% improvement[26]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 295,962,413.46, a significant increase from CNY 77,856,033.89 at the end of Q1 2022[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,716,832.96, an increase of 5.62% from the end of the previous year[6]. - Current assets as of March 31, 2023, totaled CNY 508,170,893.23, an increase of 16.4% from CNY 436,837,586.65 at the end of 2022[16]. - Non-current assets amounted to CNY 1,307,545,939.73, up from CNY 1,282,255,938.30 at the end of 2022[17]. - Total liabilities were CNY 685,161,016.86, compared to CNY 628,161,634.93 at the end of 2022, indicating a rise of 9.1%[18]. - Shareholders' equity attributable to the parent company was ¥1,127,636,203.30, up by 3.65% compared to the previous year[6]. - Shareholders' equity as of March 31, 2023, was CNY 1,130,555,816.10, an increase from CNY 1,090,931,890.02 at the end of 2022[18]. Borrowings and Financing - The company experienced a 38.83% increase in cash and cash equivalents, primarily due to increased bank borrowings[9]. - The company reported a significant increase of 126.94% in short-term borrowings, attributed to increased bank loans[9]. - Short-term borrowings increased significantly to CNY 173,602,852.77 from CNY 76,498,172.22 at the end of 2022, marking a rise of 127.5%[17]. - The company raised CNY 190,000,000.00 through borrowings in Q1 2023, compared to CNY 53,649,744.44 in the same period last year, indicating a substantial increase in financing activities[27]. Operating Costs and R&D - Total operating costs for Q1 2023 were CNY 122,646,292.57, down 2.3% from CNY 126,228,137.67 in Q1 2022[20]. - Operating costs included CNY 52,009,448.21 in cost of goods sold, which increased by 12.0% from CNY 46,376,303.16 in the previous year[20]. - Research and development expenses decreased by 30.57%, mainly due to reduced material costs and outsourced R&D expenses[10]. - The company incurred R&D expenses of CNY 8,275,164.89 in Q1 2023, down from CNY 11,918,349.97 in the same quarter last year, reflecting a 30% decrease[21]. Investment Activities - The total cash outflow from investing activities was CNY 29,010,001.14 in Q1 2023, down from CNY 88,883,426.86 in Q1 2022, showing a reduction of 67%[26].

Financial Performance - The company's operating revenue for 2022 was approximately ¥654.97 million, a decrease of 5.62% compared to ¥693.96 million in 2021[22]. - The net profit attributable to shareholders for 2022 was approximately ¥161.58 million, down 5.39% from ¥170.80 million in 2021[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥139.98 million, a decrease of 10.45% from ¥156.31 million in 2021[22]. - The cash flow from operating activities for 2022 was approximately ¥165.94 million, an increase of 15.65% compared to ¥143.49 million in 2021[22]. - The total assets at the end of 2022 were approximately ¥1.72 billion, an increase of 29.99% from ¥1.32 billion at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.09 billion, up 10.30% from ¥986.31 million at the end of 2021[22]. - Basic earnings per share for 2022 were ¥0.69, a decrease of 5.48% from ¥0.73 in 2021[23]. - The weighted average return on equity for 2022 was 15.66%, down 2.8 percentage points from 18.46% in 2021[23]. Revenue and Sales - The decline in operating revenue was primarily due to market factors affecting sales of products such as calming and brain-nourishing agents, diuretics, vitamins, and intermediates[23]. - Domestic sales accounted for CNY 628.46 million, a decline of 4.60%, while international sales fell by 28.53% to CNY 24.79 million[50]. - The company achieved over 41% market share in nine provinces for its main product, Glucosamine Hydrochloride Capsules, after winning a national procurement bid[32]. - The production of joint drugs reached 121,475.70 million units, an increase of 16.97% compared to the previous year, while sales were 120,698.31 million units, up by 15.45%[53]. - The sales of diuretic drugs decreased by 39.30% to 494.40 million units, with a sales volume of 573.92 million units, down by 20.42%[54]. - The company reported a significant decline in sales of sedative and brain-nourishing drugs, with a sales volume drop of 92.55% to 2,707.45 kg[54]. Research and Development - The company has 17 new products under research, with key products like Aspartate and Ornithine approved[33]. - The total R&D expenditure amounted to 44,304,378.52 yuan, representing 6.76% of total revenue, with a year-on-year increase of 11.56% in R&D expenses[62]. - The company is committed to continuous product research and development, focusing on anti-tumor, circulatory system, and liver protection drugs to expand its product line[41]. - The company is focusing on the consistency evaluation of 10 oral solid preparations, with key products like glucosamine hydrochloride capsules approved[102]. - The company has ongoing research projects for various chemical drugs aimed at treating conditions such as osteoarthritis, dehydration from diarrhea, and chronic hepatitis B[82]. Product Development and Innovation - The company launched four new health food products, aiming to drive sales growth through multi-channel promotion[33]. - The company has developed marine biological pharmaceutical products, primarily focusing on glucosamine hydrochloride capsules (Weiergu), with a market share of over 41% in nine provinces and cities after winning the first bid in the national centralized procurement in August 2020[35]. - The company is focusing on developing treatments for respiratory diseases and viral infections, reflecting a strategic alignment with current healthcare needs[82]. - The company has a pipeline of new products, including those targeting severe infections and heart failure, showcasing its commitment to expanding its therapeutic offerings[82]. Market Strategy and Expansion - The company plans to expand its market presence through the introduction of new drugs and technologies, focusing on therapeutic areas such as joint diseases and viral infections[70]. - The company is expanding its production capabilities with the acquisition of Fujian Huakang Pharmaceutical Co., enhancing its supply chain for key products[44]. - The company is focusing on marine pharmaceuticals, leveraging its location in Wenzhou to develop marine-based drugs[44]. - The company is actively involved in the procurement process, with significant volumes for drugs like Torasemide Injection, which had a procurement volume of 3,853,901 units[75]. Corporate Governance and Compliance - The company has established a robust governance structure to ensure compliance with laws and protect shareholder rights, with no reported issues requiring regulatory remediation[108]. - The board of directors operates independently, ensuring no undue influence from the controlling shareholder, maintaining operational autonomy[109]. - The company has implemented strict information disclosure protocols to enhance transparency and prevent insider trading, safeguarding shareholder interests[110]. - The company is committed to continuous improvement in corporate governance and internal control mechanisms to promote sustainable development[110]. Environmental and Social Responsibility - The company is committed to sustainable development and has implemented pollution prevention measures in line with clean production principles[151]. - The company has ongoing projects, including a marine biopharmaceutical manufacturing project with an annual production capacity of 1000 tons of super fish oil EPA[155]. - The company made a total charitable contribution of 300,000 RMB for public welfare projects during the reporting period[162]. - The company has established a feasible emergency response plan for environmental incidents in November 2022, which was approved by the local environmental authority[157]. Shareholder and Executive Management - The total number of shares held by the chairman, Yan Yiyi, remained unchanged at 55,137,200 shares, with a pre-tax compensation of 1.0466 million yuan[113]. - The total number of shares held by director Qiu Kerong decreased by 600,000 shares, ending the year with 1,908,800 shares, with a pre-tax compensation of 420,100 yuan[113]. - The total pre-tax compensation for all executives during the reporting period amounted to 7.8321 million yuan[114]. - The company appointed Zhao Chunjian as the new general manager and made several changes to the executive team, including the appointment of new vice presidents and a financial director[114]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion CNY[120]. - New product launches are expected to contribute an additional 200 million CNY in revenue, with a focus on innovative healthcare solutions[119]. - The company plans to increase its marketing budget by 20% to support brand awareness and customer engagement initiatives[120].

Financial Performance - The company's operating revenue for Q3 2022 was ¥158,062,744.48, representing a decrease of 4.70% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,576,202.24, down 5.47% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,221,530.94, a decrease of 5.62% compared to the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.16, reflecting a decline of 5.88% year-on-year[6] - Total operating revenue for the first three quarters of 2022 was CNY 476,221,538.79, a decrease of 9.1% compared to CNY 523,732,179.68 in the same period of 2021[19] - Net profit for the third quarter of 2022 was CNY 102,486,877.63, a decline of 13.5% from CNY 118,457,818.07 in the same quarter of 2021[20] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.44, down from CNY 0.51 in the same quarter of 2021[21] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥1,596,670,427.54, an increase of 20.73% from the end of the previous year[6] - The company's total assets as of September 30, 2022, amount to CNY 1,596,670,427.54, an increase from CNY 1,322,493,361.66 at the end of 2021[16] - Current assets total CNY 404,722,929.22, up from CNY 287,797,305.90 in the previous year[16] - Total liabilities have increased to CNY 564,438,463.48 from CNY 323,616,586.46[17] - The company has a total equity of CNY 1,032,231,964.06 as of September 30, 2022[17] - The short-term borrowings amount to CNY 101,355,636.10, an increase from CNY 86,362,967.36[16] - The long-term borrowings have significantly increased to CNY 263,592,900.95 from CNY 59,627,951.45[17] Cash Flow - The cash flow generated from operating activities for the year-to-date was ¥106,729,566.50, showing an increase of 16.37%[6] - Cash flow from operating activities for the first three quarters of 2022 was CNY 106,729,566.50, an increase of 16.4% compared to CNY 91,717,153.63 in the same period of 2021[24] - The company received CNY 485,055,716.42 in cash from operating activities during the first three quarters of 2022, compared to CNY 515,579,877.56 in the same period of 2021[24] - Cash inflow from financing activities totaled $390,265,237.08, compared to $83,107,452.81 in the previous year, marking a significant increase[25] - Net cash flow from financing activities was $194,780,298.44, a turnaround from a negative cash flow of -$29,707,148.75 in the same quarter last year[25] - Cash and cash equivalents at the end of the period reached $195,984,125.00, up from $99,047,594.61 year-over-year, indicating a strong liquidity position[25] - The net increase in cash and cash equivalents for the quarter was $114,583,665.66, compared to $26,787,024.31 in the same quarter last year, showcasing improved cash generation[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,754[12] - The largest shareholder, Yan Yiyi, holds 55,137,200 shares, representing 23.58% of total shares[12] Investment and Expenses - The company is investing in a marine biopharmaceutical manufacturing project, which has led to increased capital expenditures[10] - Research and development expenses for the first three quarters of 2022 were CNY 35,003,808.66, an increase of 18.2% from CNY 29,531,472.54 in the previous year[19] - The company reported a total investment income of CNY 35,106,827.77 for the first three quarters of 2022, up from CNY 27,366,321.15 in the same period of 2021[19] Foreign Exchange and Other Impacts - The company experienced a foreign exchange loss of CNY 3,547,000.00 in the third quarter of 2022[20] - The impact of exchange rate fluctuations on cash and cash equivalents was a positive $392,960.59, contrasting with a negative impact of -$448,695.05 last year[25]

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 318,158,794.31, a decrease of 11.10% compared to CNY 357,867,640.40 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 64,955,828.37, down 17.09% from CNY 78,349,045.35 year-on-year[18]. - The basic earnings per share decreased to CNY 0.28, down 17.65% from CNY 0.34 in the same period last year[19]. - The weighted average return on net assets was 6.44%, a decrease of 2.23 percentage points compared to 8.67% in the previous year[19]. - The decline in operating revenue was primarily due to the impact of the Shanghai pandemic, which affected sales[20]. - The net profit decline was also attributed to lower sales and underutilization of production at the subsidiary Jiangsu Chengyi, although net profit increased by 10.85% in the second quarter as the pandemic improved[20]. - The company reported a non-recurring loss of -4,619,000.00, primarily due to losses unrelated to normal business operations[22]. - The company achieved operating revenue of 318.16 million yuan, a decrease of 11.10% compared to the same period last year[34]. - Net profit attributable to shareholders was 64.96 million yuan, down 17.09% year-on-year, but showed a 10.85% increase in the second quarter as the pandemic situation improved[34]. Cash Flow and Assets - The net cash flow from operating activities increased by 31.96% to CNY 71,293,439.80, compared to CNY 54,027,637.57 in the previous year[18]. - The total assets at the end of the reporting period were CNY 1,536,858,503.24, reflecting a 16.21% increase from CNY 1,322,493,361.66 at the end of the previous year[18]. - The company reported a significant increase in cash and cash equivalents, reaching CNY 177,645,518.45, which is 113.21% higher than CNY 83,320,641.99 at the end of the previous year[43]. - The company's total assets at the end of the current period amounted to CNY 1,537,000,000, reflecting a significant increase from the previous year[43]. - The company reported a total of ¥85,971,661.34 in other payables, up from ¥62,943,714.24, indicating a growth of approximately 36.6%[108]. Research and Development - The company has 4 national new drug varieties, including 3 Class II new drugs and 1 Class IV new drug[28]. - The company has 13 invention patents and 21 utility model patents, indicating a strong focus on R&D[28]. - Research and development expenses rose by 24.51% to CNY 24,898,300.92, compared to CNY 19,996,262.19 in the previous year[40]. - The company continues to develop high-end small varieties of "marine drugs" and "medications for major diseases," with a focus on products like glucosamine hydrochloride, which has multiple specifications[34]. - The company has 11 new products under research and has successfully submitted supplementary materials for quality enhancement of existing raw materials, including glucosamine hydrochloride and vitamin K1[37]. Market Position and Strategy - The company holds 72 drug production approval numbers, with 41 products included in the national medical insurance directory[28]. - The main product, Glucosamine Hydrochloride Capsules, has achieved over 41% market share in 9 provinces and cities after winning the national procurement bid[27]. - The market for the company's main products, including Glucosamine Hydrochloride and Torasemide, is steadily growing due to their recognized efficacy[27]. - The company plans to expand its sales channels and strengthen sales process management in the upcoming period[29]. - The company is actively expanding its market presence by optimizing product structures and strengthening relationships with distributors[35]. Environmental Responsibility - The company has implemented a strategy focused on clean production and end-of-pipe treatment to enhance environmental sustainability[58]. - The company has established an emergency response plan for environmental incidents, which was reviewed and approved by the local environmental authority in November 2019[70]. - The company adheres to strict environmental standards, with maximum allowable discharge concentrations for various pollutants established[62]. - The company has not experienced any major environmental pollution incidents during the reporting period[60]. - The company has a wastewater discharge monitoring system in place, ensuring accurate data through third-party maintenance[71]. Corporate Governance and Compliance - There were significant changes in the board of directors and management, with multiple elections and appointments during the reporting period[54]. - The company has not proposed any profit distribution or capital reserve transfer plans for the half-year period[56]. - The company has not reported any changes in the controlling shareholder or actual controller during the reporting period[103]. - The company has not received any penalties or corrective actions related to legal violations during the reporting period[92]. - The company has committed to avoiding and reducing related party transactions with its subsidiaries, ensuring fair business practices[77]. Future Outlook - The company plans to enhance its market expansion strategies, focusing on increasing its market share in key regions[132]. - Future performance guidance indicates a cautious outlook, with expectations of moderate growth in the upcoming quarters[132]. - The company is committed to improving operational efficiency and reducing costs to enhance profitability[132]. - Ongoing investments in research and development are expected to yield new technologies that will support long-term strategic goals[132]. - The company plans to implement share repurchase measures to stabilize stock prices, with a maximum repurchase amount not exceeding 2% of the total share capital[86].

第一季度财务报表是否经审计 □是 √否 2022 年第一季度报告 证券代码：603811 证券简称：诚意药业 浙江诚意药业股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度(%) | | | --- | --- | --- | --- | | 营业收入 | 159,649,283.42 | | -6.75 | | 归属于上市公司股东的净利润 | 28,920,557.20 | | -36.91 | | 归属于上市公司股东的扣除非经常性 | 30,919,436.17 | | -33. ...

Financial Performance - The company's operating revenue for 2021 was approximately ¥693.96 million, a decrease of 8.46% compared to ¥758.13 million in 2020[22]. - Net profit attributable to shareholders for 2021 was approximately ¥170.80 million, representing a 3.42% increase from ¥165.14 million in 2020[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥156.31 million, up 4.48% from ¥149.60 million in 2020[22]. - The cash flow from operating activities decreased by 19.30% to approximately ¥143.49 million from ¥177.81 million in 2020[22]. - Total assets at the end of 2021 were approximately ¥1.32 billion, an increase of 9.58% from ¥1.21 billion at the end of 2020[22]. - The company's basic earnings per share for 2021 was ¥0.73, a 2.82% increase from ¥0.71 in 2020[23]. - The weighted average return on net assets decreased to 18.46%, down 1.90 percentage points from 20.36% in 2020[23]. - The decrease in operating revenue was primarily due to the impact of the pandemic and increased competition in the vitamin drug market, leading to a 43.39% decline in sales[23]. - The company reported a net asset value attributable to shareholders of approximately ¥986.31 million at the end of 2021, a 12.86% increase from ¥873.95 million at the end of 2020[22]. - The net profit attributable to shareholders increased slightly, primarily due to a 17.89% year-on-year increase in sales of joint-related drugs and increased performance compensation and investment income from Fujian Huakang[24]. Market Position and Product Development - The company's main product, glucosamine hydrochloride capsules, secured over 41% market share in nine provinces and cities after winning the third batch of national procurement[33]. - The company actively participated in pharmaceutical bidding across various provinces, enhancing its market presence and risk management[33]. - The company achieved a revenue of 2.93 trillion yuan in the pharmaceutical manufacturing industry in 2021, representing a year-on-year growth of 20.1%[36]. - The total profit for the pharmaceutical manufacturing industry reached 627.14 billion yuan in 2021, with a year-on-year increase of 77.9%[36]. - The company has 72 drug production approval numbers, with 41 included in the national medical insurance catalog and 14 in the national essential drug list[40]. - The company has 13 invention patents and 21 utility model patents, focusing on various therapeutic areas including arthritis, diuretics, and anti-tumor[40]. - The company has 14 new products under research, with key products like aspartate and ornithine raw materials approved[39]. - The company has established a subsidiary in Guangzhou with a registered capital of 10 million yuan, focusing on traditional Chinese medicine marketing and technology application services[35]. - The company has implemented a comprehensive quality management system, achieving GMP normalization and winning the Wenzhou Mayor Quality Award[34]. - The company has initiated consistency evaluation for 10 oral solid formulations, with key products like glucosamine hydrochloride capsules and tolvaptan injection successfully approved[34]. Research and Development - Research and development expenses rose by 24.92% to CNY 39.72 million, reflecting increased investment in outsourced R&D and personnel costs[51]. - The company is focused on expanding its product line with ongoing R&D in anti-tumor and liver protection drugs, enhancing long-term revenue growth prospects[48]. - The company’s R&D investment amounted to RMB 39.71 million, representing 5.72% of total revenue, with over 20 products under development focusing on marine drugs, geriatric medications, anti-tumor drugs, traditional Chinese medicine, and anti-infection drugs[86]. - The company has a total of 28 ongoing R&D projects, focusing on various therapeutic areas including antiviral and cardiovascular diseases[96]. - The company’s R&D strategy includes a focus on high-level protective drugs suitable for respiratory infections, which are critical in the current health landscape[90]. Sales and Marketing - The company has adopted a sales model that includes direct sales for raw materials and a distribution model for formulations, expanding its sales network despite pandemic challenges[41]. - The direct sales model saw a revenue decrease of 11.07%, with a gross margin of 56.13%[54]. - The company is expanding its sales coverage by optimizing its distribution network and enhancing management of regional distributors[99]. - The company has maintained strong relationships with high-end clients in Europe and the U.S. since 1998, ensuring trust through compliance with international regulations[100]. - A new marketing strategy has been implemented, focusing on digital channels, which is expected to increase customer engagement by 30%[126]. Corporate Governance and Compliance - The company has implemented a robust corporate governance structure to ensure compliance with legal requirements and protect shareholder rights[119]. - The company has implemented a comprehensive information disclosure management system to ensure transparency and protect shareholders' rights[120]. - The company continues to enhance its corporate governance structure and internal control mechanisms to promote sustainable development[120]. - The company has maintained compliance with legal and regulatory requirements regarding corporate governance[120]. - The company is committed to preventing insider trading and ensuring fair information disclosure practices[120]. Environmental Responsibility - The company reported no significant environmental pollution incidents during the reporting period, adhering to clean production principles[158]. - The company has implemented an online monitoring system for wastewater discharge, ensuring accurate data and compliance with environmental standards[167]. - The company has received environmental impact assessment approvals for multiple projects, including a 200-ton pharmaceutical raw material investment project and a 500-ton hydrochloric acid amino glucose raw material project[163]. - The company has established an emergency response plan for environmental incidents, which was approved in November 2019[166]. Shareholder Relations and Equity Management - The company has a cash dividend policy that has not been adjusted during the reporting period, with a total cash dividend of 58,447,200 RMB distributed based on a base of 166,992,000 shares, resulting in a dividend of 0.35 RMB per share[150]. - The proposed cash dividend for the 2021 fiscal year is 2.50 RMB per 10 shares, pending approval from the shareholders' meeting[151]. - The company has established a clear framework for share reduction that remains in effect regardless of changes in shareholder status or employment[184]. - The company has committed to stabilize stock prices through various measures, including share buybacks and shareholder increases[188]. - The company’s stock price stabilization measures will be initiated if the stock price falls below the latest audited net asset value due to non-force majeure factors[188]. Risks and Challenges - The company is facing potential risks from industry policy changes, including drug procurement and pricing reforms, which could impact sales and operational models[112]. - The company acknowledges the risks associated with new product development, including regulatory approval failures and market demand uncertainties[114]. - The company is aware of environmental risks related to production waste and is prepared to meet stricter future regulations[115].